Nathalie Adda - Mar 1, 2022 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Role
Sr. VP & Chief Medical Officer
Signature
/s/ Nathaniel S. Gardiner as attorney-in-fact
Stock symbol
ENTA
Transactions as of
Mar 1, 2022
Transactions value $
-$984,485
Form type
4
Date filed
3/3/2022, 05:02 PM
Previous filing
Feb 15, 2022
Next filing
Apr 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ENTA Common Stock Options Exercise $1.06M +24.3K +69.58% $43.46 59.3K Mar 1, 2022 Direct
transaction ENTA Common Stock Sale -$1.7M -24.2K -40.86% $70.26* 35.1K Mar 1, 2022 Direct F1, F2
transaction ENTA Common Stock Sale -$7.11K -100 -0.29% $71.06* 35K Mar 1, 2022 Direct F1
transaction ENTA Common Stock Options Exercise $542K +12.5K +35.68% $43.46 47.5K Mar 2, 2022 Direct
transaction ENTA Common Stock Sale -$875K -12.5K -26.3% $70.07* 35K Mar 2, 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ENTA Stock Option (Right to Buy) Options Exercise $0 -24.3K -66.1% $0.00 12.5K Mar 1, 2022 Common Stock 24.3K $43.46 Direct F4
transaction ENTA Stock Option (Right to Buy) Options Exercise $0 -12.5K -100% $0.00* 0 Mar 2, 2022 Common Stock 12.5K $43.46 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.97, inclusive.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.28, inclusive.
F4 100% of the shares subject to the option are fully vested and exercisable.

Remarks:

The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 above.